Company: EVGN
Filing Date: 2025-03-27
Form Type: 20-F
Source: 0001178913-25-001092
Chunk: 240

Company: Evogene Ltd.
Filing Date: 2025-03-27
Form: 20-F
Item: Item 9
Chunk 240
---

to serve as the placement agent for Evogene in connection with the 2024 Offering. We agreed to pay AGP a cash placement fee equal to 7.0%
of the gross proceeds received from the sale of the securities sold in the 2024 Offering.

Controlled Equity Offering Sales Agreements

On January 14, 2021 and February 19, 2021, we entered into Controlled
Equity OfferingSMSales Agreements, or the January
Sales Agreement and February Sales Agreement, respectively, with Cantor Fitzgerald & Co., or the Agent, pursuant to which the Company
could offer and sell, from time to time, its ordinary shares, through the Agent in an at-the-market offering, as defined in Rule 415(a)(4)
promulgated under the Securities Act, for an aggregate offering price of up to $28.0 million and $50.0 million (subsequently reduced to
approximately $19.5 million), respectively. Information on that transaction is set forth in this Annual Report under “ Item 5. Operating
and Financial Review and Prospects - B. Liquidity and Capital Resources - Recent Public Offerings of Ordinary Shares - Cantor
Controlled Equity OfferingSMSales Agreement” and
is incorporated by reference herein. The January Sales Agreement and February Sales Agreement were each terminated as of March 2024.
For the years ended December 31, 2023 and 2024, we received cumulative aggregate gross proceeds of approximately $700,000 under the January
Sales Agreement and February Sales Agreement.

Lavie Bio SAFE with ICL

In August 2022, ICL invested (through an affiliate company)
in Lavie Bio $10 million under a SAFE (simple agreement for future equity). Information on that transaction is set forth in this Annual
Report under “ Item 4. Information on the Company - B. Business Overview - Market Segments - Agriculture - Lavie
Bio Ltd. - Key Collaborations - ICL Group” and is incorporated by reference herein.

Biomica Share Purchase Agreement with SHC

On April 27, 2023, we announced the closing of a definitive
agreement for a $20 million financing round in Biomica, led by a $10 million investment from SHC, with an additional $10 million invested
by Evogene. Following the closing of this transaction, we hold approximately 67% of the share capital of Biomica, while SHC holds approximately
20%, in each case on a fully